102 However, a number of teams are advocating for the incorporation of novel markers, like a elaborate karyotype55 or epigenetic subsets, 27,28 into clinical practice. All of these novel prognostic and/or predictive designs will should be validated in cohorts of individuals addressed with focused brokers.That notwithstanding, both of those subtypes